Last reviewed · How we verify
LCP-tacrolimus QD + MMF BID
LCP-tacrolimus is a prolonged-release formulation of tacrolimus combined with mycophenolate mofetil (MMF) to suppress T-cell mediated immune responses and prevent organ rejection.
LCP-tacrolimus is a prolonged-release formulation of tacrolimus combined with mycophenolate mofetil (MMF) to suppress T-cell mediated immune responses and prevent organ rejection. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver transplantation).
At a glance
| Generic name | LCP-tacrolimus QD + MMF BID |
|---|---|
| Sponsor | University Hospital, Limoges |
| Drug class | Calcineurin inhibitor + antimetabolite combination |
| Target | Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Tacrolimus is a calcineurin inhibitor that blocks T-cell activation by inhibiting IL-2 production, while MMF is an inosine monophosphate dehydrogenase inhibitor that selectively suppresses lymphocyte proliferation. The LCP (Lipid Conjugate Platform) formulation provides once-daily dosing of tacrolimus, improving adherence in immunosuppressive regimens. Together, these agents provide complementary immunosuppression for transplant rejection prevention.
Approved indications
- Prevention of organ rejection in transplant recipients (kidney, heart, liver transplantation)
Common side effects
- Nephrotoxicity
- Neurotoxicity (tremor, headache)
- Hyperglycemia
- Hypertension
- Gastrointestinal disturbances
- Infections
- Leukopenia
Key clinical trials
- Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (PHASE4)
- Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LCP-tacrolimus QD + MMF BID CI brief — competitive landscape report
- LCP-tacrolimus QD + MMF BID updates RSS · CI watch RSS
- University Hospital, Limoges portfolio CI